

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4858374

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT		
CONVEYING PARTY DATA			
Name			Execution Date
NEUROPORE THERAPIES, INC.			02/13/2018
RECEIVING PARTY DATA			
Name:	UCB BIOPHARMA SPRL		
Street Address:	ALLÉE DE LA RECHERCHE 60		
City:	BRUSSELS		
State/Country:	BELGIUM		
Postal Code:	1070		
PROPERTY NUMBERS Total: 2			
Property Type	Number		
Application Number:	62198515		
Application Number:	15748154		
CORRESPONDENCE DATA			
Fax Number:	(858)720-5125		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	8587205100		
Email:	jthomas@mofo.com		
Correspondent Name:	LISA SILVERMAN		
Address Line 1:	MORRISON & FOERSTER LLP		
Address Line 2:	12531 HIGH BLUFF DRIVE, SUITE 100		
Address Line 4:	SAN DIEGO, CALIFORNIA 92130		
ATTORNEY DOCKET NUMBER:	699462000900		
NAME OF SUBMITTER:	LISA N. SILVERMAN		
SIGNATURE:	/Lisa N. Silverman/		
DATE SIGNED:	03/08/2018		
Total Attachments: 4			
source=Neuropore-UCB Assignment_6994620009xx#page1.tif			
source=Neuropore-UCB Assignment_6994620009xx#page2.tif			
source=Neuropore-UCB Assignment_6994620009xx#page3.tif			
source=Neuropore-UCB Assignment_6994620009xx#page4.tif			

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: Neuropore Therapies, Inc.
 Address: 10835 Road to the Cure, Suite 230, San Diego, CA 92121
 A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignor"), which was the sole and exclusive owner, by assignment, of the patent applications identified below:

Serial No.: 62/198,515	Filing Date: July 29, 2015
Serial No.: PCT/US2016/044871	Filing Date: July 29, 2016

This Assignment is to:

Assignee: UCB BIOPHARMA SPRL
 Address: Allée de la Recherche 60, 1070 Brussels, Belgium
 A juristic entity duly organized under and pursuant to the laws of Belgium

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent applications.

Assignors previously assigned the above-mentioned applications for letters patent to Assignee in an agreement executed January 12, 2018 (the "Prior Assignment").

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

1. To the extent that Assignors have not already done so via a prior agreement with the Assignee (including through the Prior Assignment), or if Assignors have already done so via a prior agreement with the Assignee then in confirmation of any obligation to do so in said prior agreement, Assignors have and do hereby sell, assign, transfer and set over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned applications for letters patent, and any and all provisionals, non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignors represent, warrant and covenant (a) that, at the time of execution and delivery of this agreement, Assignors are the sole and lawful owners of their entire right, title and interest in and to said applications for letters patent, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignors solely and lawfully owned the entire right, title and interest in and to said applications for letters patent, and that the same were unencumbered and that Assignors sold, assigned, transferred and set over to Assignee and its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to applications for letters patent.

3. Assignor shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said application for letters patent; (b) any provisional, non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof; or any substitution of any such application; (c) any letters patent or patents which may be granted thereon in any country or jurisdiction, including without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding; with the exception that Assignor shall bear certain costs as set forth in the Prior Assignment. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.
4. Assignor hereby authorizes and requests the Commissioner of Patents in the United States to issue the above mentioned letters patent of the United States to Assignee as the assignee of said patent applications and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.
5. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.
6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: Feb 13 2018

Signature: 
 Name: DOUG BONHAUS
 Title: C.S.O.
 Company: NEUROPORE THERAPIES, INC.

ASSIGNEE:

Date: _____

Signature: _____
 Name: _____
 Title: _____
 Company: UCB BIOPHARMA SPRL

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: Neuropore Therapies, Inc.
 Address: 10835 Road to the Cure, Suite 230, San Diego, CA 92121
 A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignor"), which was the sole and exclusive owner, by assignment, of the patent applications identified below:

Serial No.: 62/198,515	Filing Date: July 29, 2015
Serial No.: PCT/US2016/044871	Filing Date: July 29, 2016

This Assignment is to:

Assignee: UCB BIOPHARMA SPRL
 Address: Allée de la Recherche 60, 1070 Brussels, Belgium
 A juristic entity duly organized under and pursuant to the laws of Belgium

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent applications.

Assignors previously assigned the above-mentioned applications for letters patent to Assignee in an agreement executed January 12, 2018 (the "Prior Assignment").

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

1. To the extent that Assignors have not already done so via a prior agreement with the Assignee (including through the Prior Assignment), or if Assignors have already done so via a prior agreement with the Assignee then in confirmation of any obligation to do so in said prior agreement, Assignors have and do hereby sell, assign, transfer and set over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned applications for letters patent, and any and all provisionals, non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignors represent, warrant and covenant (a) that, at the time of execution and delivery of this agreement, Assignors are the sole and lawful owners of their entire right, title and interest in and to said applications for letters patent, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignors solely and lawfully owned the entire right, title and interest in and to said applications for letters patent, and that the same were unencumbered and that Assignors sold, assigned, transferred and set over to Assignee and its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to applications for letters patent.

3. Assignor shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said application for letters patent; (b) any provisional, non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof; or any substitution of any such application; (c) any letters patent or patents which may be granted thereon in any country or jurisdiction, including without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding; with the exception that Assignor shall bear certain costs as set forth in the Prior Assignment. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.
4. Assignor hereby authorizes and requests the Commissioner of Patents in the United States to issue the above mentioned letters patent of the United States to Assignee as the assignee of said patent applications and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.
5. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.
6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: _____

Signature: _____

Name: _____

Title: _____

Company: NEUROPORE THERAPIES, INC.

ASSIGNEE:

Date: February 27, 2018

Signature: _____

Name: _____

Title: _____

Company: UCB BIOPHARMA SPRL